Our Platform Technology
The investigational Lumicell™ Direct Visualization System (DVS)* has the potential to guide the removal of residual cancer in real time, thereby identifying cancer during the initial surgery that may otherwise remain undetected and recur or require a second surgery to address.
The system is comprised of an optical imaging agent, handheld device and patient-calibrated tumor detection software that work in concert to find, view and guide the resection of residual cancer after the surgeon is believed to be done with the initial tumor removal.
LUMISIGHT*, an investigational proprietary onco-fluorescent agent, is administered pre-operatively (same day) to highlight cancer cells.
The hand-held imaging probe enables surgeon to scan, inside the breast cavity, to find activated LUMISIGHT in residual cancer.
Real-time images from the cavity based on a patient-calibrated tumor detection software, guides the surgeon in removal of residual cancerous tissue.
Watch a Case Study
*CAUTION: LUMISIGHT and Lumicell Direct Visualization System (DVS) are investigational products that are limited by Federal (or United States) law to investigational use. LUMISIGHT and Lumicell DVS are not authorized for marketing for any indication in any jurisdiction.